NCT05665751View on ClinicalTrials.gov

A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Insulin Resistance
Interventions
DRUG

TLC-3595 Dose 1

Tablets administered orally

DRUG

TLC-3595 Dose 2

Tablets administered orally

DRUG

Placebo

Tablets administered orally

Trial Locations (4)

1010

OrsoBio Reseach Site, Auckland

OrsoBio Research Site, Auckland

8011

OrsoBio Research Site, Christchurch

0626

OrsoBio Research Site, Auckland

Sponsors

Lead Sponsor

OrsoBio, Inc
All Listed Sponsors
lead

OrsoBio, Inc

INDUSTRY

NCT05665751 - A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance | Biotech Hunter | Biotech Hunter